HWH International Inc.
HWH International Inc. (HWH): 29 pipeline candidates · 5 upcoming catalysts · ~28 mo cash runway · 89 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
28.4 months
0% dilution
Lead: Approved
29 candidates
5 upcoming, next in ~166d
4 buys · 1 sell (180d)
A transparent, data-derived signal for HWH International Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$12.6M
Cash
$1.5M
Quarterly Burn
$193K
Runway
28.4 mo
Revenue
$64K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (29 candidates)
| Drug | Phase |
|---|---|
| [prp] platelet rich plasma | Phase 2 |
| [stromed + platelet rich plasma] | Phase 2 |
| a multicenter access | — |
| brinzolamide; brimonidine | Approved |
| cd33cart allogeneic | Phase 1/Phase 2 |
| cd33cart autologous | Phase 1/Phase 2 |
| conditioning regimen a | Phase 2 |
| conditioning regimen b | Phase 2 |
| conditioning regimen c | Phase 2 |
| conditioning regimen d | Phase 2 |
Showing 10 of 29 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Frequently asked questions
How many drug candidates are in HWH International Inc.'s pipeline?
HWH International Inc. (HWH) has 29 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HWH International Inc.'s lead drug candidate?
HWH International Inc.'s most advanced tracked candidate is [prp] platelet rich plasma (Phase 2) for Osteoarthritis.
What is HWH International Inc.'s next catalyst?
HWH International Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase 2 Randomized Controlled Study of Revumenib as Maintenance Therapy After Allogeneic Hematopoiet" — expected December 1, 2026.
What is HWH International Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HWH International Inc. has approximately 28.4 months of cash runway.
What is HWH International Inc.'s market capitalization?
HWH International Inc.'s market capitalization is approximately $12.6M.
Get the full picture on HWH International Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.